

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 1 of 12

ATTORNEY DOCKET No.	SERIAL NO.	
6102-000049/US/NP	10/599,976	
APPLICANT		
Scheller, D. & Stoehr, T.		
FILING DATE	GROUP	
October 16, 2006	1614	

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/Subclass	Filing Date
L1		4,303,673	Dec 1, 1981	Biedermann et al.	424/324	
L2		4,510,082	Apr 9, 1985	Gesellchen & Shuman	260/112.5R	
L3		4,513,009	Apr 23, 1985	Roques et al.	514/513	
L4		4,533,657	Aug 6, 1985	Morgan	514/19	
L5		4,618,708	Oct 21, 1986	Roques et al.	562/448	
L6		4,707,468	Nov 17, 1987	Yoshino et al.	514/16	
L7		5,378,729	Jan 3, 1995	Kohn & Watson	514/231.2	
L8		5,508,266	Apr 16, 1996	Fink	514/19	
L9		5,536,853	Jul 16, 1996	Spellmeyer et al.	549/441	
L10		5,656,267	Aug 12, 1997	Sagen & Pappas	424/93.21	
L11		5,760,038	Jun 2, 1998	Murugesan et al.	514/252	
L12		5,773,475	Jun 30, 1998	Kohn	514/616	
L13		5,780,589	Jul 14, 1998	Lazarus et al.	530/331	
L14		5,866,585	Feb 2, 1999	Fogel	514/289	
L15		5,885,999	Mar 23, 1999	Elliott et al.	514/258	
L16		6,001,876	Dec 14, 1999	Singh	514/561	
L17		6,028,102	Feb 22, 2000	Bialer et al.	514/489	Feb 24, 1998
L18		6,037,324	Mar 14, 2000	Schwender & Shroff	514/18	Jan 4, 1996
L19		6,083,941	Jul 4, 2000	Farb	514/177	Jul 24, 1996
L20		6,083,951	Jul 4, 2000	Bradbury	514/256	Dec 14, 1998
L21		6,103,732	Aug 15, 2000	Amberg et al.	514/269	Apr 4, 1997
L22		6,114,390	Sep 5, 2000	Engel et al.	514/595	Oct 14, 1997
L23		6,126,939	Oct 3, 2000	Eisenbach-Schwartz et al.	424/185.1	May 28, 1997
L24		6,180,611	Jan 30, 2001	Montana et al.	514/19	May 20, 1999
L25		6,277,825	Aug 21, 2001	Olivera et al.	514/13	Jul 20, 1999
L26		6,737,408	May 18, 2004	Balasubramanium et al.	514/18	Jul 18, 2000
L27		2003/0216466	Nov 20, 2003	Scheuerman et al.	514/513	May 13, 2003

Examiner:	Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 2 of 12

ATTORNEY DOCKET NO.	SERIAL NO.
6102-000049/US/NP	10/599,976
APPLICANT	
Scheller, D. & Stoehr, T.	
FILING DATE	GROUP
October 16, 2006	1614

U.S. P	U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/Subclass	Filing Date	
L28		2004/0101582	May 27, 2004	Wolicki	424/760	Nov 25, 2002	
L29		2005/0013856	Jan 20, 2005	Trivedi & Gokhale	424/464	Dec 18, 2003	
L30		2005/0043675	Feb 24, 2005	Pastore et al.	604/67	Aug 21, 2003	
L31		2005/0227961	Oct 13, 2005	Kucharik & Speicher	514/211.13	Nov 30, 2004	
L32		2005/0261204	Nov 24, 2005	Stoehr	514/19	May 16, 2005	
L33		2005/0277596	Dec 15, 2005	Stoehr	514/19	Jun 7, 2005	
L34		2005/0288234	Dec 29, 2005	Stoehr	514/19	Jun 10, 2005	
L35		2006/0009384	Jan 12, 2006	Rudd & Stoehr	514/12	Dec 3, 2004	
L36		2006/0046957	Mar 2, 2006	Beyreuther & Stoehr	514/7	Aug 26, 2005	
L37		2006/0135437	Jun 22, 2006	Stoehr & Rausschkolb-Loeffler	514/19	Jun 9, 2005	

FOREI	GN PATENT	DOCUMENTS					
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/Subclass	Transl Yes	ation No
L38		DE 195 33 023	Apr 18, 1996	Germany	C07D 239/60	Х	
L39		EP 0 555 537	Aug 18, 1993	EPO	C07K 5/06		
L40		EP 0 997 147	May 3, 2000	EPO	A61K 31/165		
L41		EP 1 243 263	Nov 27, 2002	EPO EPO	A61K 31/165		
L42		EP 1 486 205	Dec 15, 2004	EPO	A61K 31/16		
L43		EP 1 486 206	Dec 15, 2004	EPO EPO	A61K 31/16		
L44		EP 1 537 862	Jun 8, 2005	EPO	A61K 31/165		
L45		EP 1 541 138	Jun 15, 2005	EPO	A61K 31/165		
L46		EP 1 579 858	Sep 28, 2005	EPO	A61K 31/165		
L47		EP 1 688 137	Aug 9, 2006	EPO	A61K 31/165		
L48		WO 92/14706	Sep 3, 1992	WIPO	C07D 207/16	,	
L49		WO 95/30645	Nov 16, 1995	WIPO	C07C 233/11		
L50		WO 96/11209	Apr 18, 1996	WIPO	C07K 5/06		

Fi	
Examiner:	Date Considered:

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 3 of 12

ATTORNEY DOCKET No.	SERIAL NO.
6102-000049/US/NP	10/599,976
APPLICANT	
Scheller, D. & Stoehr, T.	
FILING DATE	GROUP
October 16, 2006	1614

Ref. Examiner's Initials		Document Number	Publication Date	Country	Class/Subclass	Translation Yes No	
L51		WO 96/32100	Oct 17, 1996	WIPO	A61K 31/165		
L52		WO 97/38980	Oct. 23, 1997	WIPO	C07D 239/52	Х	
L53		WO 97/38981	Oct. 23, 1997	WIPO	C07D 239/52	Х	
L54		WO 98/09953	Mar. 12, 1998	WIPO	C07D 237/52	Х	
L55		WO 99/02146	Jan 21, 1999	WIPO	A61K 31/165		Х
L56		WO 99/07413	Feb 18, 1999	WIPO	A61K 45/06		
L57		WO 99/16444	Apr 8, 1999	WIPO	A61K 31/505	Х	
L58		WO 99/23078	May 14, 1999	WIPO	C07D 239/00	Х	
L59		WO 99/43309	Sep 2, 1999	WIPO	A61K 31/00		
L60		WO 00/51586	Sep 8, 2000	WIPO	A61K 31/00		
L61		WO 01/17976	Mar 15, 2001	WIPO	C07D 239/69		
L62		WO 01/78762	Oct 25, 2001	WIPO	A61K 38/22		
L63		WO 02/13766	Feb 21, 2002	WIPO	A61K		
L64		WO 02/15922	Feb 28, 2002	WIPO	A61K 38/00		
L65		WO 02/42256	May 30, 2002	WIPO	C07C 237/06		
L66		WO 02/74297	Sep 26, 2002	WIPO	A61K 31/165		
L67		WO 02/74784	Sep 26, 2002	WIPO	C07K		
L68		WO 02/76979	Oct 3, 2002	WIPO	C07D 403/12		
L69		WO 02/87548	Nov 7, 2002	WIPO	A61K 9/20		
L70		WO 02/88664	Nov 7, 2002	WIPO	G01N		
L71		WO 03/000642	Jan 3, 2003	WIPO	C07C 203/04		
L72		WO 04/014895	Feb 19, 2004	WIPO	C07D 403/04		
L73		WO 04/043926	May 27, 2004	WIPO	C07D 213/64		
L74		WO 04/046178	Jun 3, 2004	WIPO	C07K 14/435		
L75		WO 04/060353	Jul 22, 2004	WIPO	A61K 9/16		
L76		WO 04/066987	Aug 12, 2004	WIPO	A61K 31/00		

Examiner:		Date Con	sidered:	

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 4 of 12

ATTORNEY DOCKET No.	SERIAL NO.	
6102-000049/US/NP	10/599,976	
APPLICANT		
Scheller, D. & Stoehr, T.		
FILING DATE	GROUP	
October 16, 2006	1614	

FOREIGN PATENT DOCUMENTS							
Ref. Examiner's Initials	Document Number	Publication Date	Country	Class/Subclass	Translation Yes No		
L77		WO 04/066990	Aug 12, 2004	WIPO	A61K 31/135		
L78		WO 04/091585	Oct 28, 2004	WIPO	A61K 9/20		
L79		WO 04/100871	Nov 25, 2004	WIPO	A61K		
L80		WO 05/053667	Jun 16, 2005	WIPO	A61K 31/165		
L81		WO 05/092313	Oct 6, 2005	WIPO	A61K 31/165		
L82		WO 05/099740	Oct 6, 2005	WIPO	A61K 38/05		
L83		WO 05/120539	Dec 22, 2005	WIPO	A61K 38/00		

Ref. Desig.	Examiner's Initials	
L84		Abbott et al. (1995) Pain 60:91–102
L85		Abdulla & Smith (2002) J. Neurophysiol. 88:2518–2529
L86		Akiba et al. (2003) Receptors & Channels 9:291299
L87		Albensi et al. (2004) Am. J. Alzheimer's Disease & Other Dementias 19:269–274
L88		Amir et al. (2006) J. Pain 7(5 Suppl. 3):S1–S29
L89		Arnér & Meyerson (1988) Pain 33:11–23
L90		Arnt et al. (1984) Pol. J. Pharmacol. Pharm. 36:221–230
L91		Arroyo (2003) "Safety of SPM 927 in subjects with epilepsy and neuropathic pain" Poster presented at AES Scientific Exhibit, December 5–10, 2003
L92		Backonja (2002) Neurology 59:S14-S17
L93		Backonja (2003) Anesth. Analg. 97:785–790
L94		Béguin et al. (2003) Bioorganic & Medicinal Chemistry 11:4275–4285
L95		Béguin et al. (2004) Bioorganic & Medicinal Chemistry 12:3079–3096
L96		Ben-Menachem (2005) "A dose-response, placebo-controlled trial using lacosamide as adjunctive therapy in subjects with partial seizures" Presented at 26th International Epilepsy Congress, Paris, Aug 28 – Sep 1, 2005

Examiner:	Date Considered:

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 5 of 12

ATTORNEY DOCKET No.	SERIAL NO.		
6102-000049/US/NP	10/599,976		
APPLICANT			
Scheller, D. & Stoehr, T.			
FILING DATE	GROUP		
October 16, 2006	1614		

OTHER DOCUMENTS				
Ref. Desig.	Examiner's Initials			
L97		Ben-Menachem et al. (2005) "Efficacy and safety of adjunctive oral lacosamide for the treatment of partial- onset seizures in patients with epilepsy" Poster P03.101 presented at American Academy of Neurology 57th Annual Meeting, Miami Beach, FL		
L98		Bennett & Xie (1988) Pain 33(1):87–107 (abstract only <a href="http://www.ncbi.nlm.nih.gov/pubmed/2837713">http://www.ncbi.nlm.nih.gov/pubmed/2837713</a> )		
L99		Bennett et al. (2000) Pain 86:163–175		
L100		Beyak et al. (2004) Am. J. Physiol. Gastrointest. Liver Physiol. 287:G845–G855		
L101		Beyreuther (2004) "Pharmacology of SPM 927 and its relevance to clinical practice for neuropathic pain" Presented at Visiongain Pain Management, 2004		
L102		Beyreuther et al. (2004) "SPM 927 displays potent antinococeptive effects in rat models for inflammatory and neuropathic pain" Poster presented at Neuropathic Pain, May 13–14, 2004		
L103		Beyreuther et al. (2005) "Lacosamide displays antinociceptive effects in a rat model for tumor-induced cancer pain and chemotherapy-induced pain" Poster presented at World Congress on Pain, August 21–26, 2005		
L104		Beyreuther et al. (2005) "Lacosamide displays antinociceptive effects in a rat model for diabetic neuropathic pain" Presented at World Congress on Pain, August 21–26, 2005		
L105		Beyreuther et al. (2006) "Effects of lacosamide as compared to other analgesics: a responder analysis in the streptozotocin rat model for diabetic neuropathic pain" Poster 618 presented at American Pain Society, 2006 (abstract at <a href="http://www.ampainsoc.org/db2/abstract/view?poster_id=2637#618">http://www.ampainsoc.org/db2/abstract/view?poster_id=2637#618</a> )		
L106		Beyreuther et al. (2006) "Lacosamide displays antinociceptive effects in a rat model for musculoskeletal pain induced by TNF" Poster 625 presented at American Pain Society, 2006 (abstract at <a href="http://www.ampainsoc.org/db2/abstract/view?poster-id=2643#625">http://www.ampainsoc.org/db2/abstract/view?poster-id=2643#625</a> )		
L107		Beyreuther et al. (2006) "Lacosamide displays antinociceptive effects in rat models for arthritis pain" Poster 626 presented at American Pain Society, 2006 (abstract at <a href="http://www.ampainsoc.org/db2/abstract/view?poster-id=2644#626">http://www.ampainsoc.org/db2/abstract/view?poster-id=2644#626</a> )		
L108		Beyreuther et al. (2006) Eur. J. Pharmacol. 539:64–70		
L109		Beyreuther et al. (2007) CNS Drug Rev. 13(1):21–42		
L110		Beyreuther et al. (2007) Arthritis Res. Therapy 9:R14, http://arthritis-research.com/content/9/1/R14		
L111		Bialer et al. (2001) Epilepsy Res. 43:11–58		
L112		Bialer et al. (2002) Epilepsy Res. 51:31–71		
L113		Bilsky et al. (2000) J. Med. Chem. 43:2586–2590		
L114		Biton et al. (2003) Epilepsia 44(Suppl. 9):259, abst. 2.241 (copy of poster attached)		
L115		Biton et al. (2004) "Safety and tolerability of lacosamide solution for infusion" Poster presented at AES Scientific Exhibit, December 3–7, 2004		

Examiner:		<del></del>	- <del>-</del>	Date Considered:

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 6 of 12

ATTORNEY DOCKET No.	SERIAL NO.		
6102-000049/US/NP	10/599,976		
APPLICANT			
Scheller, D. & Stoehr, T.			
FILING DATE	GROUP		
October 16, 2006	1614		

	R DOCUMEN	13
Ref. Desig.	Examiner's Initials	
L116		Biton et al. (2005) "Safety and tolerability of intravenous lacosamide as replacement for oral lacosamide in subjects with partial seizures" Poster P02.148 presented at International Epilepsy Congress, August 28 - September 1, 2005
L117		Biton (2006) "Multicenter, double-blind, double-dummy trial investigating safety, tolerability and pharmacokinetics of intravenous lacosamide (SPM 927) in subjects with partial seizures" Presented at European Congress on Epileptology 2006
L118		Blackburn-Munro et al. (2002) Eur. J. Pharmacol. 445:231–238
L119		Blair & Bean (2002) J. Neurosci. 22(23):10277-10290
L120		Blair & Bean (2003) J. Neurosci. 23(32):10338-10350
L121		Bolay et al., (2002) "Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine". Nat. Med. 8:136-42
L122		Bretschneider et al. (2006) http://www.ampainsoc.org/db2/abstract/view?poster_id=2765#766
L123		Brodie (1996) Can. J. Neurol. Sci. 23(Suppl. 2):S6-S9
L124		Bunney & Garland (1982) Pharmacopsychiat. 15:111–115
L125		Caliendo et al. (2005) Curr. Med. Chem. 12(15):1721–1753
L126		Calvino et al. (1987) Behavioural Brain Res. 24:11–29
L127		Casey et al. (2003) Neuropsychopharmacol. 28:182–192
L128		Cawello et al. (2003) Epilepsia 44(Suppl. 9):95, abst. 1.265 (copy of poster attached)
L129		Cawello et al. (2004) Epilepsia 45(Suppl. 7):307, abst. 2.342 (copy of poster attached)
L130		Chen & Lipton (2006) J. Neurochem. 97:1611–1626
L131		Chevrier et al. (2004) Br. J. Pharmacol. 142:576–584
L132		Christensen et al. (1996) Pain 68:97–107
L133		Citrome (2003) Psychopharmacol. Bull. 37(Suppl. 2):74–88
L134		Colpaert et al. (1982) Life Sciences 31:67–75
L135		Cummins et al. (2004) J. Neurosci. 24(38):8232–8236
L136		Daniels et al. (2005) "Long-term safety and efficacy of lacosamide as adjunctive therapy in subjects with partial seizures: 96-week follow-up" Poster presented at AES Scientific Exhibit, December 2–5, 2005
L137		Decosterd & Woolf (2000) Pain 87:149–158
L138		Doty et al. (2004) in Bialer et al., Epilepsy Res. 61:1–48, pp. 14–16

Examiner:	Date Considered:

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 7 of 12

ATTORNEY DOCKET No.	SERIAL NO.	
6102-000049/US/NP	10/599,976	
APPLICANT		
Scheller, D. & Stoehr, T.		
FILING DATE	GROUP	
October 16, 2006	1614	

OTHER DOCUMENTS				
Ref. Desig.	Examiner's Initials			
L139		Doty et al. (2004) "Update on the clinical development of SPM 927 (formerly harkoseride)" Presented at EILAT VII, May 2004		
L140		Dowdall et al. (2005) Pharmacol. Biochem. Behavior 80:93–108		
L141		Dubuisson & Dennis (1977) Pain 4:161–174		
L142		Duncan & Kohn (2005) Epilepsy Res. 67:8187		
L143		Eller et al. (2005) Neurosurg. Focus 18(5):E3, 3 pp.		
L144		Elliott (1997) Brain Res. 754:221–226		
L145		Erichsen & Blackburn-Munro (2002) Pain 98:151–161		
L146		Errington et al. (2005) "Lacosamide has a unique molecular mode of action" Poster presented at AES Scientific Exhibit, December 2–5, 2005		
L147		Everill et al. (2001) Neurosci. 106(1):161–169		
L148		Field et al. (1997) Br. J. Pharmacol. 121:1513–1522		
L149		Field et al. (2002) J. Pharmacol. Exp. Ther. 303(2):730–735		
L150		Fountain et al. (2000) Epilepsia 41(Suppl. 7):169 (copy of presentation attached)		
L151		Freynhagen et al. (2005) Pain 115:254–263		
L152		Grippo et al. (2005) Psychopharmacol. 179:769–780		
L153		Hama et al. (1999) Pharmacol. Biochem. Behavior 62:67–74		
L154		Han et al. (2000) Pain 84:253–261		
L155		Hao et al. (2004) "SPM 927, a new anti-epileptic drug, alleviates neuropathic pain-like behaviors in rats after spinal cord or trigeminal nerve injury" Poster presented at Neuropathic Pain – Changing Paradigms in Diagnosis and Treatment, Madrid, May 2004		
L156		Heers et al. (2006) "The preclinical profile of the novel anticonvulsant lacosamide" Poster presented at European Congress on Epileptology 2006		
L157		Henriksson (1999) Baillière's Clin. Rheumatol. 13(3):455–461		
L158		Hidvegi et al. (2006) "Lacosamide in subjects with painful distal diabetic neuropathy: results of a multi-center, open-label, follow-on trial" Poster presented at American Pain Society, May 3–6, 2006		
L159		Hofmann et al. (2003) Eur. J. Pharmacol. 470:17–25		
L160		Holmberg et al. (2004) J. Med. Chem. 47:3927–3930		
L161		Hong et al. (2004) J. Biol. Chem. 279(28):29341–29350		

Examiner:	Date Considered:

# PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 8 of 12

ATTORNEY DOCKET No.	SERIAL NO.		
6102-000049/US/NP	10/599,976		
APPLICANT			
Scheller, D. & Stoehr, T.			
FILING DATE	GROUP		
October 16, 2006	1614		

OTHER	OTHER DOCUMENTS		
Ref. Desig.	Examiner's Initials		
L162		Honore et al. (2000) Neurosci. 98(3):585–598	
L163		Horstmann et al. (2002) Epilepsia 43(Suppl. 7):188, abst. 2.174 (copy of poster attached)	
L164		Horstmann et al. (2003) Epilepsia 44(Suppl. 9):97, Abst. 1.271 (copy of poster attached)	
L165		Horstmann et al. (2003) "SPM 927 does not prolong the QTc interval" Poster presented at 6th International Conference on the Mechanisms and Treatment of Neuropathic Pain, San Francisco, Sep 18–20, 2003	
L166		Hovinga (2003) IDrugs 6(5):479–485	
L167		Hunskaar et al. (1985) J. Neurosci. Methods 14:69–76	
L168		Hunt (2003) Clin. Orthopaedics Rel. Res. 409:96–105	
L169		Hurley et al. (2002) Anesthesiology 97:1263–1273	
L170		Ilyin et al. (2005) Br. J. Pharmacol. 144:801–812	
L171		Jain (2000) Emerging Drugs 5(2):241–257	
L172		Jensen (2000) Eur. J. Neurol. 7(Suppl. 3):3-4, abst. MT-9	
L173		Kalso (2005) Curr. Pharm. Design 11:3005–3011	
L174		Kemp & McKernan (2002) Nature Neurosci. Suppl. 5:1039–1042	
L175		Kenney et al. (2006) http://www.ampainsoc.org/db2/abstract/view?poster_id=2773#774	
L176		Kim & Chung (1992) Pain 50(3):355–363	
L177		Kropeit et al. (2004) Epilepsia 45(Suppl. 7): 123, abst. 1.323 (copy of poster attached)	
L178		Kropeit et al. (2005) "Low drug-interaction potential of Lacosamide" Poster 702 presented at American Pain Society 2005 (abstract at <a href="http://www.ampainsoc.org/db2/abstract/view?poster-id=2394#702">http://www.ampainsoc.org/db2/abstract/view?poster-id=2394#702</a> )	
L179		Kropeit et al. (2006) "Lacosamide has low potential for drug-drug-interaction" Poster 851 presented at American Pain Society 2006 (abstract at <a href="http://www.ampainsoc.org/db2/abstract/view?poster">http://www.ampainsoc.org/db2/abstract/view?poster</a> id=2848 #851)	
L180		Lai et al. (2003) Curr. Opin. Neurobiol. 13:291–297	
L181		Lai et al. (2004) Ann. Rev. Pharmacol. Toxicol. 44:371–397	
L182		Lampert et al. (2006) Exp. Brain Res. 174(4):660–666	
L183		Lawand et al. (1997) Eur. J. Pharmacol. 324:169–177	
L184		Leao AAP (1994) "Spreading depression of activity in the cerebral cortex". J. Neurophysiol. 7:359-390.	
L185		Lee et al. (2000) NeuroReport 11(4):657 - 661	

Examiner:	Date Considered:

# PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 9 of 12

ATTORNEY DOCKET No.	SERIAL NO.	
6102-000049/US/NP	10/599,976	
APPLICANT		
Scheller, D. & Stoehr, T.		
FILING DATE	GROUP	
October 16, 2006	1614	

OTHER DOCUMENTS		
Ref. Desig.	Examiner's Initials	
L186		Lee et al. (2002) J. Biol. Chem. 277(8):6542–6549
L187		Lesser et al. (2004) Neurology 63:2104–2110
L188		LeTiran et al. (2002) J. Med. Chem. 45:4762-4773
L189		Lockwood et al. (2002) N. Engl. J. Med. 347(12):904–910
L190		Lu & Westlund (1999) J. Pharmacol. Exp. Ther. 290:214–219
L191		Lynch et al. (2004) Pain 110:56–63
L192		Mach et al. (2002) Neurosci. 113(1):155–166
L193		Macres (2000) "Understanding neuropathic pain" <a href="http://www.spineuniverse.com/displayarticle.php/article1614.">http://www.spineuniverse.com/displayarticle.php/article1614.</a>
L194		Maier et al. (2004) "A pilot randomized, double-blind, placebo-controlled pilot trial to investigate safety and efficacy of SPM 927 in subjects with postherpetic neuralgia" Poster presented at Neuropathic Pain, May 13–14, 2004
L195		Majumdar et al. (2004) Eur. J. Neurosci. 20:127–143
L196		March (1985) Advanced Organic Chemistry, New York: Wiley, pp. 16–18
L197		McCleane (2003) CNS Drugs 17(14):1031–1043
L198		McCleane et al. (2003) Neurosci. Lett. 352:117-120
L199		Meinardi (1995) in Levy et al., ed. "Antiepileptic Drugs", 4th ed., chap. 6, pp. 91–97; New York: Raven Press
L200		Mohapatra et al. (2003) Mol. Cell. Neurosci. 23:314–324
L201		Moller (2000) J. Am. Acad. Audiol. 11(3):115–124
L202		Morrow et al. (2001) Soc. Neurosci. Conf. Abst. 508
L203		Morrow et al. (2003) "The effects of lacosamide in animal models for acute, inflammatory and neuropathic pain" Poster presented at AES Scientific Exhibit, December 5–10, 2003
L204		Nakata et al. (2003) Biol. Psychiatry 53:571–576
L205		Papapetropoulos & Singer (2007) Seminars in Neurology 27(2):183–194
L206		Patel et al. (2001) Pain 90:217–226
L207		Pessoa-Mahana et al. (2003) Mini Rev. Med. Chem. 3:77–93
L208		Priestley (2004) Curr. Drug Targets – CNS & Neurol. Disorders 3:441–456
L209		Randall & Selitto (1957) Arch. Int. Pharmacodyn. 91:409-419

Examiner:	Date Considered:

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 10 of 12

ATTORNEY DOCKET No.	SERIAL NO.	
6102-000049/US/NP	10/599,976	
APPLICANT		
Scheller, D. & Stoehr, T.		
FILING DATE	GROUP	
October 16, 2006	1614	

OTHE	OTHER DOCUMENTS		
Ref. Desig.	Examiner's Initials		
L210		Rauck et al. (2003) "A randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of SPM 927 in painful diabetic neuropathy" Poster presented at 6th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, Sep 2003	
L211		Rauck et al. (2007) Clin. J. Pain 23(2):150–158	
L212		Rauschkolb et al. (2004) "SPM 927, a novel promising pain treatment" Presented at Visiongain Pain Management, 2004	
L213		Remy et al. (2004) Neuropharmacol. 47:1102–1112	
L214		Richeimer (2000) "The Richeimer Pain Update" http://www.helpforpain.com/arch2000dec.htm	
L215		Rodger (1991) Can. Med. Assoc. J. 145:1571–1581	
L216		Rosenfeld et al. (2003) Epilepsia 44(Suppl. 9):262, abst. 2.249 (copy of poster attached)	
L217		Rosenfeld et al. (2005) Epilepsia 46(Suppl. 8):184, abst. 2.278 (copy of poster attached)	
L218		Rosenstock et al. (2004) Pain 110:628–638	
L219		Rüttiger et al. (2003) Hear. Res. 180:39–50	
L220		Sachdeo et al. (2003) "An open-label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures" Poster presented at 55th Annual Meeting, American Academy of Neurology, March 2003	
L221		Saddi & Abbott (2000) Pain 89:53–63	
L222		Schiltmeyer et al. (2004) Epilepsia 45(Suppl. 7):313, abst. 2.361 (copy of poster attached)	
L223		Schiltmeyer et al. (2006) "No interaction between lacosamide and metformin" Poster 850 presented at American Pain Society 2006 (abstract at <a href="http://www.ampainsoc.org/db2/abstract/view?poster_id=2847_#850">http://www.ampainsoc.org/db2/abstract/view?poster_id=2847_#850</a> )	
L224		Seltzer et al. (2001) Pain 93:101–106	
L225		Shaibani et al. (2005) "An open-label follow-on trial to assess the long-term safety and efficacy of oral lacosamide in subjects with diabetic neuropathy" Poster presented at World Congress on Pain, August 21–26, 2005	
L226		Shiro et al. (1996) Psychiatry Clin. Neurosci. 50:141–146	
L227		Silver & Soderlund (2005) Neurotoxicol. 26:397–406	
L228		Sindrup & Jensen (1999) Pain 83:389–400	
L229		Sommerville (2003) "Schwarz Pharma's Neurology Pipeline" <a href="http://www.schwarzpharma.com/uploads/assets/1369-4-neurology-KNS-190203.pdf">http://www.schwarzpharma.com/uploads/assets/1369-4-neurology-KNS-190203.pdf</a>	

Examiner:	Date Considered:

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 11 of 12

ATTORNEY DOCKET No.	SERIAL NO.
6102-000049/US/NP	10/599,976
APPLICANT	
Scheller, D. & Stoehr, T.	
FILING DATE	GROUP
October 16, 2006	1614

OTHER DOCUMENTS		
Ref. Desig.	Examiner's Initials	
L230		Sommerville & Whitesides (2004) "Intravenous SPM 927 (formerly harkoseride)" Presented at EILAT VII, May 2004
L231		Stein et al. (1988) Pharmacol. Biochem. Behavior 31:445–451
L232		Stoehr et al. (2005) "Lacosamide displays potent antinociceptive effects in animal models for neuropathic and inflammatory pain" Poster presented at World Congress on Pain, August 21–26, 2005
L233		Stoehr & Beyreuther (2005) "The effect of lacosamide in comparison to other analgesics in rat models for neuropathic pain" Poster presented at 8th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, San Francisco, November 3–5, 2005
L234		Stoehr et al. (2006) Eur. J. Pain 10:241–249
L235		Teng & Abbott (1998) Pain 76:337–347
L236		Tjølsen (1992) Pain 51:5–17
L237		Tjølsen & Hole (1997) in Dickinson & Besson, ed., "The Pharmacology of Pain", chap. 1, pp. 1–20; Berlin: Springer-Verlag
L238		Vaiciene et al. (2006) "Multicenter, open-label trial investigating safety and tolerability of intravenous lacosamide (SPM 927) as replacement for oral lacosamide in subjects with partial seizures: report of first cohort" Poster presented at European Congress on Epileptology 2006
L239		Vos et al. (1994) J. Neurosci. 14(5):2708–2723
L240		Watson et al. (1997) Pain 70:53–58
L241		Wheeler-Aceto et al. (1990) Pain 40:229–238
L242		Wheeler-Aceto & Cowan (1991) Psychopharmacol. 104:35–44
L243		Whitesides et al. (2004) "Long-term safety and efficacy of lacosamide as adjunctive therapy in subjects with partial seizures: 48-week follow-up" Poster presented at AES Scientific Exhibit, December 3–7, 2004
L244		Wood et al. (2002) in "Sodium Channels and Neuronal Hyperexcitability", pp. 159–172; Chichester: Wiley
L245		Wood et al. (2004) J. Neurobiol. 61:55–71
L246		Wu et al. (2005) J. Physiol. 565.2:371–380
L247		Wymer et al. (2005) "A multi-center, randomized double-blind, placebo-controlled trial to assess the efficacy and safety of lacosamide in subjects with painful distal diabetic neuropathy." 8th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, San Francisco, Nov 3–5, 2005
L248		Xu et al. (1992) Pain 48(2):279–290 (abstract only)
L249		Yezierski et al. (1998) Pain 75:141–155

Examiner:	Date Considered:
	Date Combidered.

#### PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 12 of 12

ATTORNEY DOCKET No.	SERIAL NO.	
6102-000049/US/NP	10/599,976	
APPLICANT		
Scheller, D. & Stoehr, T.		
FILING DATE	GROUP	
October 16, 2006	1614	

OTHER DOCUMENTS		
Ref. Desig.	Examiner's Initials	
L250		Ziegler et al. (2005) "Efficacy and safety of lacosamide in the treatment of neuropathic pain attributed to distal diabetic neuropathy." 8th Int. Conf. on Mechanisms and Treatment of Neuropathic Pain, San Francisco, November 3–5, 2005

Examiner:	Date Considered:
Examiner.	Date Considered.